Bayer AG vowed to defend its embattled weedkiller Roundup, moving to reassure investors that its $63 billion acquisition of Monsanto Co. will boost the company’s bottom line.
The multibillion-dollar settlement Bayer announced in June to resolve thousands of Roundup cancer cases is stalled, lawyers said Thursday during a status conference before a federal judge.
Glyphosate – the weedkiller better known by its most-famous brand name Roundup – does not have the best of public profiles.